2021 Annual Meeting - Management of a Tonsil Cancer Patient: From Work-up through Late Radiation Toxicity
This session will guide the audience through a very practical approach to work up and management of an HPV+ tonsil cancer patient (T1N1), from initial examination and work-up through late complications. A community radiation oncologist, a medical oncologist, and a speech therapist will discuss current work up, staging, treatment including contouring and DVH evaluation. We will discuss recommended concurrent chemo regimens summarizing the latest literature on weekly vs q3week cis, mentioning recent RTOG 1016 and DeESCALaTE results, data on 30mg/m2 vs 40mg/m2 weekly cis, common chemotherapy side effects and management of those side effects, amount/timing of recommended IV fluid supplementation, and laboratory monitoring (timing of WBC nadir) Additionally reasons we will cover when to give non-cisplatin regimens and what the recommended alternatives are. Our speech therapist will present on preferred timing of referrals, guidance provided during radiation therapy, when/how often/patient symptoms to indicate swallow study, type of study to order, how/when to wean them off feeding tube, and late dysphagia assessments.
The activity is designed to meet the interests of radiation oncologists and radiation oncology residents, medical oncologists and radiation physicists.
Upon completion of this activity, participants should be able to:
- Analyze current clinical data and understand evolving approaches to the management of head and neck cancer.
- Determine appropriate referrals, timing, and expectations from speech therapy.
- Thomas P. Boike, MD, MMM, Genesis Care / Michigan Healthcare Professionals and receives compensation from Boston Scientific and Blue Earth.
- Arshin Sheybani, MD, John Stoddard Cancer Center and has no financial relationships with a commercial interest.
- Carryn M. Anderson, MD, University of Iowa Hospitals & Clinics and receives compensation from Elekta. Dr. Anderson is an Iowa Association of Nurse Anesthetists Officer/Board Member.
- Katharine Price, MD, Division of Medical Oncology, Mayo Clinic and has no financial relationships with a commercial interest.
- Teresa Lyden, MA, Department of Otolaryngology, University of Michigan and has no financial relationships with a commercial interest.
The person(s) above served as the developer(s) of this activity. Additionally, the Education Committee had control over the content of this activity. All relevant relationships have been mitigated.
The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council of Continuing Medical Education to provide continuing education to physicians.
ASTRO is awarded Deemed Status by the American Board of Radiology to provide SA-CME as part of Part II Maintenance of Certification.
- 1.00 Certificate of AttendanceThis activity was designated for 1.00 AMA PRA Category 1 Credit™.
- 1.00 SA-CME
The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council of Continuing Medical Education to provide continuing medical education for physicians.
The American Society for Radiation Oncology (ASTRO) designates this for a maximum of 1.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This activity meets the American Board of Radiology's criteria for a self-assessment activity in the ABR's Maintenance of Certification program. Participation in this course in combination with the successful completion of the corresponding assessment and course evaluation adheres to the guidelines established by the ABR for 1.00 self-assessment credits.
• No refunds, extensions or substitutions will be made for those registrants who, for any reason, were unable to attend or were tardy for the session.
• No credits will be granted and no refunds, exchanges or transfers will be given to those who do not pass.
• ASTRO staff cannot make modifications to your submitted materials.
One of the two latest versions of Google Chrome, Mozilla Firefox, Internet Explorer or Safari.